EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

The effect of metformin on the pharmacokinetics of rifampicin, isoniazid, and pyrazinamide in adults with tuberculosis

Jacques Rossouw iD, Robert Wallis, Hardy Kornfeld iD, Amit Singhal iD, Gary Maartens iD, Lubbe Wiesner iD, Paolo Denti iD, Roeland E Wasmann iD

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.00748-26 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Jacques Rossouw und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Hauptthemen laut MEDLINE: Antitubercular Agents, Isoniazid, Metformin, Pyrazinamide. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metformin is under investigation as adjunctive host-directed therapy for tuberculosis (TB), which might interact with first-line TB treatment. We used population pharmacokinetic modeling to assess whether metformin alters first-line TB-drug pharmacokinetics in HIV/TB-coinfected adults without diabetes. Rifampicin, isoniazid, and pyrazinamide pharmacokinetics were investigated in participants from a randomized clinical trial of adjunctive metformin (500 mg twice daily to week 12) in adults starting HIV-associated TB treatment. Antiretroviral therapy (ART)-naïve participants initiated dolutegravir-based ART within 8 weeks. Intensive and semi-intensive sampling was conducted at week 5; concentration–time data were analyzed using non-linear mixed-effects modeling. Data from 78 individuals (43 receiving metformin, median weight 60.8 kg, 62.8% male, 79.5% on ART) were analyzed. Rifampicin and pyrazinamide were described by one-compartment models with linear elimination; typical clearances were 15.8 L/h (95% CI: 13.5–18.7) and 3.88 L/h (95% CI: 3.54–4.08), respectively. Isoniazid followed a two-compartment model with a mixture model for acetylator status; clearance was 10.5 L/h (95% CI: 9.44–11.9) in slow acetylators and 28.8 L/h (95% CI: 25.6–31.0) in fast/intermediate acetylators. Metformin reduced isoniazid bioavailability by 15.6% (95% CI: 4.45–26.4%, P < 0.009) and rifampicin bioavailability by 24.0% (95% CI: 7.83–36.3%, P < 0.007), decreasing the area under the curve from 0 to 24 h from 18.2 to 15.6 mg·h/L and from 35.9 to 27.1 mg·h/L, respectively. No significant effect on pyrazinamide was detected. We found that non-diabetic patients on metformin had lower isoniazid and rifampicin bioavailability. Lowered rifampicin exposure might be clinically relevant; simulations suggest that this could be offset by a single 150 mg rifampicin dose. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT04930744 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsIsoniazidMetforminPyrazinamideRifampinTuberculosisAdultFemaleHumansMaleMiddle AgedDrug InteractionsHIV Infections

Stichwörter der Autor:innen

Mycobacterium tuberculosisdrug–drug interactionfirst-line TB treatmentpharmacometricspopulation pharmacokinetic modeling

Substanzen

Antitubercular AgentsIsoniazidMetforminPyrazinamideRifampin

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
  • The Aurum Institute, Johannesburg, South Africa.
  • Department of Medicine, UMass Chan Medical School, Worcester, Massachusetts, USA.
  • A*STAR Infectious Diseases Labs, Agency for Science Technology and Research (A*STAR), Singapore, Republic of Singapore.

ORCID-Profile: Jacques Rossouw, Hardy Kornfeld, Amit Singhal, Gary Maartens, Lubbe Wiesner, Paolo Denti, Roeland E Wasmann

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Rossouw, J., Wallis, R., Kornfeld, H., Singhal, A., Maartens, G., Wiesner, L., Denti, P., & Wasmann, R. E. (2026). The effect of metformin on the pharmacokinetics of rifampicin, isoniazid, and pyrazinamide in adults with tuberculosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00748-26

Vancouver

Rossouw J, Wallis R, Kornfeld H, Singhal A, Maartens G, Wiesner L, et al. The effect of metformin on the pharmacokinetics of rifampicin, isoniazid, and pyrazinamide in adults with tuberculosis. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00748-26

BibTeX
@article{Rossouw2026,
  author = {Rossouw, Jacques and Wallis, Robert and Kornfeld, Hardy and Singhal, Amit and Maartens, Gary and Wiesner, Lubbe and Denti, Paolo and Wasmann, Roeland E},
  title = {The effect of metformin on the pharmacokinetics of rifampicin, isoniazid, and pyrazinamide in adults with tuberculosis},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.00748-26}
}
Kostenlos starten →